Shuttle Pharmaceuticals Holdings (SHPH) Cash & Equivalents (2021 - 2026)

Shuttle Pharmaceuticals Holdings' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 76.44% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 76.44% decrease from a year earlier, with the FY2025 full-year figure at $257955.0, down 86.57% from the prior year.
• Cash & Equivalents advanced to $1.1 million in Q1 2026 per SHPH's latest filing, from $257955.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $9.1 million in Q3 2022 and bottomed at $156656.0 in Q3 2024.
• The 5-year median for Cash & Equivalents is $2.6 million (2023), against an average of $3.2 million.
• Across the five-year window, Cash & Equivalents jumped 6191.01% in 2022 and sank 94.54% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $5.4 million in 2022, then tumbled by 52.39% to $2.6 million in 2023, then declined by 25.47% to $1.9 million in 2024, then slumped by 86.57% to $257955.0 in 2025, then surged by 312.0% to $1.1 million in 2026.
• Per Business Quant, the three latest SHPH Cash & Equivalents figures stand at $1.1 million (Q1 2026), $257955.0 (Q4 2025), and $2.1 million (Q3 2025).